Falk Gastro Review Journal

Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

The latest issues

Edition 4/2024

Edition 3/2024

Edition 2/2024

Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

All articles

Earlier anti-TNF initiation leads to long-term lower health care utilization in Crohn’s disease but not in ulcerative colitis

Clin Gastroenterol Hepatol. 2022;20(11):2607–18.e14

The association between non-steroidal anti-inflammatory drug use and inflammatory bowel disease exacerbations: A true association or residual bias?

Am J Gastroenterol. 2022;117(11):1851–7

Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease

Clin Gastroenterol Hepatol. 2022;20(11):2577–87.e6

Effect of 5-hydroxytryptophan on fatigue in quiescent inflammatory bowel disease: A randomized controlled trial

Gastroenterology. 2022;163(5):1294–305.e3

Ustekinumab during pregnancy in patients with inflammatory bowel disease: A prospective multicenter cohort study

Aliment Pharmacol Ther. 2022;56(9):1361–9

Corticosteroids and mesalamine versus corticosteroids for acute severe ulcerative colitis: A randomized controlled trial

Clin Gastroenterol Hepatol. 2022;20(12):2868–75.e1

ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomized, placebo-controlled induction trial and 48 week, open-label extension

Lancet Gastroenterol Hepatol. 2022;7(11):1024–35

The rising burden of inflammatory bowel disease in Denmark over 2 decades: A nationwide cohort study

Gastroenterology. 2022;163(6):1547–54.e5

Efficacy and safety of ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: A phase 2 study

Gastroenterology. 2022;163(6):1555–68